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Abstract
Background: Primary traumatic mechanical injury to the spinal cord (SCI) causes the death of a number of neurons that to
date can neither be recovered nor regenerated. During the last years our group has been involved in the design, synthesis
and evaluation of PDE7 inhibitors as new innovative drugs for several neurological disorders. Our working hypothesis is
based on two different facts. Firstly, neuroinflammation is modulated by cAMP levels, thus the key role for
phosphodiesterases (PDEs), which hydrolyze cAMP, is undoubtedly demonstrated. On the other hand, PDE7 is expressed
simultaneously on leukocytes and on the brain, highlighting the potential crucial role of PDE7 as drug target for
neuroinflammation.
Methodology/Principal Findings: Here we present two chemically diverse families of PDE7 inhibitors, designed using
computational techniques such as virtual screening and neuronal networks. We report their biological profile and their
efficacy in an experimental SCI model induced by the application of vascular clips (force of 24 g) to the dura via a four-level
T5–T8 laminectomy. We have selected two candidates, namely S14 and VP1.15, as PDE7 inhibitors. These compounds
increase cAMP production both in macrophage and neuronal cell lines. Regarding drug-like properties, compounds were
able to cross the blood brain barrier using parallel artificial membranes (PAMPA) methodology. SCI in mice resulted in
severe trauma characterized by edema, neutrophil infiltration, and production of a range of inflammatory mediators, tissue
damage, and apoptosis. Treatment of the mice with S14 and VP1.15, two PDE7 inhibitors, significantly reduced the degree
of spinal cord inflammation, tissue injury (histological score), and TNF-a, IL-6, COX-2 and iNOS expression.
Conclusions/Significance: All these data together led us to propose PDE7 inhibitors, and specifically S14 and VP1.15, as
potential drug candidates to be further studied for the treatment of SCI.
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Introduction
Spinal cord injury (SCI) is a highly debilitating pathology [1].
Although innovative medical care has improved patient outcome,
advances in pharmacotherapy for the purpose of decrease
neuronal injury and promoting regeneration have been limited.
The complex pathophysiology of SCI may explain the difficulty in
finding a suitable therapy.
An excessive post-traumatic inflammatory reaction may play an
important role in the secondary injury processes, which develop
after SCI [2]. The primary traumatic mechanical injury to the
spinal cord causes the death of a number of neurons that to date
can neither be recovered nor regenerated. However, neurons
continue to die for hours after SCI, and this represents a
potentially avoidable event [3]. This secondary neuronal death is
determined by a large number of cellular, molecular, and
biochemical cascades. One such cascade that has been proposed
to contribute significantly to the evolution of the secondary
damage is the local inflammatory response in the injured spinal
cord. Recent evidence, however, suggests that leukocytes,
especially neutrophils which are the first leukocytes to arrive
within the injured spinal cord [4], may also be directly involved in
the pathogenesis and extension of spinal cord injury in rats.
Several authors have demonstrated that neutrophils are especially
prominent in a ‘marginal zone’ around the main area of injury and
infarction at 24 h [5].
The cardinal features of inflammation, namely infiltration of
inflammatory cells (not only polymorphonuclear neutrophils but
also macrophage and lymphocytes), release of inflammatory
mediators, and activation of endothelial cells leading to increased
vascular permeability, edema formation, and tissue destruction
have been widely characterized in animal models of SCI [6]. Both
necrotic and apoptotic mechanisms of cell death after SCI then,
have been well and extensively described in animal SCI models
[7].
Phosphodiesterases (PDEs) are a large family of metallopho-
sphohydrolase enzymes that ubiquitously metabolize the second
messengers adenosine and guanosine 39,59-cyclic monophosphates
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phates[8]. cAMP and cGMP are synthesized by adenylyl and
guanylyl cyclases respectively, and mediate the action of
hormones, neurotransmitters, and other cellular effectors in many
physiologic processes. As elevation of intracellular cAMP level
impacts immunosuppressive and anti-inflammatory properties
[9,10], selective inhibitors of cAMP-specific PDEs have been
widely studied as therapeutics for the treatment of human diseases
[11], predominantly immune disorders such as multiple sclero-
sis[12] and inflammatory processes [13], and also disorders of the
central nervous system (CNS) such as depression, psychosis, and
Alzheimer’s disease[14].
To date, most of the research has been centered on PDE4
inhibitors because PDE4 represents the major isoenzyme in most
T-cell preparations and its selective inhibitors are able to decrease
inflammatory cytokine production [15,16]. PDE4 inhibitors have
been widely studied as anti-inflammatory agents for the treatment
of inflammatory disease and multiple sclerosis [17]. However, a
major drawback of these compounds is the significant side effects
such as emesis. To overcome these adverse effects, several
strategies to dissociate the beneficial and detrimental effects of
PDE4 inhibitors have led to some degree of success and the second
generation of PDE4 inhibitors have shown better pharmacokinetic
profiles[18]. An alternative approach is to target other cAMP-
specific PDE families that are expressed in pro-inflammatory and
immune cells. Initial evidence indicated that PDE7 had an
important role in the activation of T-cells [19,20]. However,
results based on the use of PDE7A knockout mice (PDE7A
_/
_)
failed to confirm the role of PDE7A in T-cell proliferation and
suggested that this phosphodiesterase could have some other role
in the regulation of humoral immune responses [21]. Thus,
selective PDE7A inhibitors would be essential to elucidate the true
potential of PDE7A as a pharmacological target in the context of
the immune and neurological responses [22,23]. The latest
scientific findings concerning PDE7 and PDE4 inhibition suggest
that selective small-molecule inhibitors of both enzymes could
provide a novel approach to treat a variety of immunological
diseases. In this context, our ligand-based virtual screening studies
allowed us to identify quinazoline derivatives as a new class of
PDE7 inhibitors [24]. This new family of inhibitors increases
cAMP production both in macrophage and neuronal cell lines and
reduces the inflammatory response induced by lipopolysacharide
treatment in both types of cells cultures [25]. More recently, we
have developed a neuronal network able to predict PDE7
inhibition activity of new molecules [26]. Using this drug discovery
computational model, we have shown the PDE7 inhibitory
properties of the 5-imino-1,2,4-thiadiazole heterocyclic family
[27]. Here we present pharmacological properties of two
chemically diverse families of PDE7 inhibitors (see chemical
structure in Fig. 1a and b), designed using computational
techniques such as virtual screening and neuronal networks. We
report their CNS penetration properties, and their efficacy in an
experimental SCI model. In particular, we have determined the
following endpoints of the inflammatory response: (1) histological
damage, (2) motor recovery, (3) neutrophil infiltration, (4) NF-kB
expression, (5) iNOS formation, (6) pro-inflammatory cytokines
production, and (7) apoptosis as Bax and Bcl-2 expression.
Materials and Methods
Animals
Male adult CD1 mice (25–30 g, Harlan Nossan, Milan, Italy)
were used for all studies. Mice were housed in individual cages (5
for each group) and maintained under 12:12 light-dark cycle at
2161uC and 5065% humidity. The animals were acclimated to
their environment for 1 wk and had ad libitum access to tap water
and standard rodent standard diet. All animal experiments
complied with regulations in Italy (D.M. 116192), Europe (O.J.
of E.C. L 358/1 12/18/1986) and USA (Animal Welfare
Assurance No A5594-01, Department of Health and Human
Services, USA). All behavioral testing was conducted in compli-
ance with the NHI laboratory animal care guidelines and with
protocols approved by the Institutional Animal Care and Use
Committee (Council directive # 87-848, October 19, 1987,
Ministe `re de l’Agriculture et de la Fore ˆt, Service Ve ´te ´rinaire de la
Sante ´ et de la Protection Animale, permission # 92-256 to SC).
The study was approved by the University of Messina Review
Board for the care of animals (PRIN ID 1042).
SCI
Mice were anaesthetized using chloral hydrate (400 mg/kg
body weight). We used the clip compression model described by
Rivlin and Tator [28] and produced SCI by extradural
compression of a section of the SC exposed via a four-level T5-
T8 laminectomy, in which the prominent spinous process of T-5
was used as a surgical guide. A six-level laminectomy was chosen
to expedite timely harvest and to obtain enough SC tissue for
biochemical examination. With the aneurysm clip applicator
oriented in the bilateral direction, an aneurysm clip with a closing
force of 24 g was applied extradurally at T5-T-8 level. The clip
was then rapidly released with the clip applicator, which caused
SC compression. In the injured groups, the cord was compressed
for 1min. Following surgery, 1.0 cc of saline was administered
subcutaneously in order to replace the blood volume lost during
the surgery. During recovery from anesthesia, the mice were
placed on a warm heating pad and covered with a warm towel.
The mice were singly housed in a temperature-controlled room at
27uC for a survival period of 10 days. Food and water were
provided to the mice ad libitum. During this time period, the
animals’ bladders were manually voided twice a day until the mice
were able to regain normal bladder function. Sham injured
animals were only subjected to laminectomy.
Experimental Design
Mice were randomized into 6 groups (N=40 animals/group).
Sham animals were subjected to the surgical procedure except
that the aneurysm clip was not applied and treated intraperito-
neally (i.p.) with vehicle (10% DMSO) or S14 (10 mg/kg) or
VP1.15 (4 mg/kg) 1 h, 3 h and 6 h after surgical procedure. The
remaining mice were subjected to SCI (as described above) and
treated with an i.p. bolus of vehicle (10% DMSO) or S14 (10 mg/
kg) or VP1.15 (4 mg/kg) 1 h, 3 h and 6 h after SCI. The doses of
S14 or VP1.15 used here were based on their PDE7 IC50 values
(5.5 and 1.1 mM, respectively) and our experience on previous
studies [29]. To investigate the motor score, in other set of
experiments, the animals were treated with S14 (10 mg/kg) or
VP1.15 (4 mg/kg) 1 h, 3 h and 6 h after SCI and daily until day
9. Ten mice from each group were sacrificed at different time
points in order to collect samples for the evaluation of the
parameters as described below.
Myeloperoxidase activity
Myeloperoxidase (MPO) activity, an indicator of polymorpho-
nuclear leukocyte (PMN) accumulation, was determined in the
spinal cord tissues as previously described [30] at 24 hours after
SCI. At the specified time following SCI, spinal cord tissues were
obtained and weighed and each piece homogenized in a solution
containing 0.5% (w/v) hexadecyltrimethyl-ammonium bromide
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centrifuged for 30 min at 20,000 x g at 4uC. An aliquot of the
supernatant was then allowed to react with a solution of 1.6 mM
tetramethylbenzidine and 0.1 mM H2O2. The rate of change in
absorbance was measured spectrophotometrically at 650 nm.
MPO activity was defined as the quantity of enzyme degrading
1 mmol of peroxide per min at 37uC and was expressed as units of
MPO/mg of proteins.
Immunohistochemical localization of IL-1b, TNF-a, iNOS
and COX-2
At the end of the experiment, the tissues were fixed in 10% (w/v)
PBS-buffered formaldehyde and 8 mm sections were prepared from
paraffin embedded tissues. After deparaffinization, endogenous
peroxidase was quenched with 0.3% (v/v) hydrogen peroxide in
60% (v/v) methanol for 30 min. The sections were permeabilized
with 0.1% (w/v) Triton X-100 in PBS for 20 min. Non-specific
adsorption was minimized by incubating the section in 2% (v/v)
normal goat serum in PBS for 20 min. Endogenous biotin or avidin
binding sites were blocked by sequential incubation for 15 min with
biotin and avidin, respectively. Sections were incubated overnight
with anti-COX-2 antibody (Santa Cruz Biotechnology, 1:500 in
PBS, v/v), anti-TNF-a ligand antibody (Santa Cruz Biotechnology,
1:500 in PBS, v/v), anti-IL-1b ligand antibody (Santa Cruz
Biotechnology, 1:500 in PBS, v/v), anti-iNOS antibody (Santa
Cruz Biotechnology, 1:500 in PBS, v/v). Sections were washed with
PBS, and incubated with secondary antibody. Specific labeling was
detected with a biotin-conjugated goat anti-rabbit IgG and avidin-
biotin peroxidase complex (Vector Laboratories, DBA).
In order to verify the binding specificity for IL-1b, TNF-a,
iNOS and COX-2 some sections were also incubated with only
the primary antibody (no secondary) or with only the secondary
antibody (no primary). In these situations no positive staining was
found in the sections indicating that the immunoreaction was
positive in all the experiments carried out. Immunocytochemistry
photographs (n=5) were assessed by densitometry. The assay was
carried out by using Optilab Graftek software on a Macintosh
personal computer (CPU G3-266). All the immunocytochemistry
analysis was carried out without knowledge of the treatments.
Western blot analysis for IkB-a, Bax, Bcl-2 and pERK-1/2
Cytosolic and nuclear extracts were prepared as previously
described [31] with slight modifications. Briefly, spinal cord tissues
from each mouse were suspended in extraction Buffer A containing
0.2 mM PMSF, 0,15 mM pepstatin A, 20 mM leupeptin, 1 mM
sodium orthovanadate, homogenized at the highest setting for
2 min, and centrifuged at 1,000 x g for 10 min at 4uC.
Supernatants represented the cytosolic fraction. The pellets,
containing enriched nuclei, were re-suspended in Buffer B
containing 1% Triton X-100, 150 mM NaCl, 10 mM TRIS-HCl
pH 7.4, 1 mM EGTA, 1 mM EDTA, 0,2 mM PMSF, 20 mm
leupeptin, 0,2 mM sodium orthovanadate. After centrifugation
30 min at 15,000 x g at 4uC, the supernatants containing the
nuclear protein werestoredat 280forfurtheranalysis.Thelevelsof
IkB-a, Bax, and Bcl-2 were quantified in cytosolic fraction from
spinal cord tissue collected after 24 hours after SCI. The filters were
blocked with 1x PBS, 5% (w/v) non fat dried milk (PM) for 40 min
at room temperature and subsequently probed with specific Abs
IkB-a (Santa Cruz Biotechnology, 1:1000), or anti-Bax (1:500;
Santa Cruz Biotechnology), or anti-Bcl-2 (1:500; Santa Cruz
Biotechnology), in 1x PBS, 5% w/v non fat dried milk, 0.1%
Tween-20 (PMT) at 4uC, overnight. Membranes were incubated
with peroxidase-conjugated bovine anti-mouse IgG secondary
antibody or peroxidase-conjugated goat anti-rabbit IgG (1:2000,
Jackson ImmunoResearch, West Grove, PA) for 1 h at room
temperature. To ascertain that blots were loaded with equal
Figure 1. PDE7 inhibitors and their chemical structures. a and b represent a chemical structures of VP1,15 and S14respectively. In order in the
spinal cord tissue collected from SCI mice, was observed the alteration of morphology of neurons when compared with sham-operated mice (Fig d
and c respectively). A protection against alteration of neuron’s morphology was observed in mice group treated with VP 1.15 and S14 (e, f
respectively).
doi:10.1371/journal.pone.0015937.g001
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of the antibody against b-actin protein (1:10,000 Sigma-Aldrich
Corp.). The relative expression of the protein bands of IkB-a
(,37 kDa), Bax (,23 kDa), Bcl-2 (,29 kDa) was quantified by
densitometric scanning of the X-ray films with GS-700 Imaging
Densitometer (GS-700, Bio-Rad Laboratories, Milan, Italy) and a
computer program (Molecular Analyst, IBM), and standardized for
densitometric analysis to b-actin levels. The dual-phosphorylated
form of ERK (p-ERK) antibody identified two bands of
approximately 44 and 42 kDa (corresponding to p-ERK1 and p-
ERK2, respectively). The anti-ERK2 antibody detects total ERK2
(i.e. detects both phosphorylated and nonphosphorylated forms of
ERK2).
Light microscopy
Spinal cord tissues were taken at 24 h following trauma. Tissue
segments containing the lesion (1 cm on each side of the lesion)
were paraffin embedded and cut into 5-mm-thick sections. Tissue
sections (thickness 5 mm) were deparaffinized with xylene, stained
with Haematoxylin/Eosin (H&E), with methyl green pyronin
staining (used to simultaneously DNA and RNA) and studied using
light microscopy (Dialux 22 Leitz).
The segments of each spinal cord were evaluated by an
experienced histopathologist. Damaged neurons were counted and
the histopathologic changes of the gray matter were scored on a 6-
point scale [32]: 0, no lesion observed, 1, gray matter contained 1
to 5 eosinophilic neurons; 2, gray matter contained 5 to 10
eosinophilic neurons; 3, gray matter contained more than 10
eosinophilic neurons; 4, small infarction (less than one third of the
gray matter area); 5, moderate infarction; (one third to one half of
the gray matter area); 6, large infarction (more than half of the
gray matter area). The scores from all the sections from each spinal
cord were averaged to give a final score for individual mice. All the
histological studies were performed in a blinded fashion.
Golgi impregnation
FD Neurotech kit (FD NeuroTechnologies, Ellicott City, Md,
USA) was used for Golgi impregnation of spinal cord tissue. Blocks
were placed directly into solutions A and B, without rinsing, and
remained there for 2 weeks in the dark at room temperature.
Forty-eight hours after placing the blocks in solution C (4uC), the
blocks were frozen on dry ice and stored at 270uC until
sectioning. Cryostat sections (100 mm) were cut at 225uC and
mounted onto gelatinized slides. Slides were allowed to dry in the
dark, and the rest of the staining process done as previously
described.
Neurons chosen for tracing met the following criteria: (1) they
were completely impregnated with Golgi stain, (2) they were
unobscured by other impregnated neurons or precipitant, (3) 70%
of the dendritic tree was visible within the plane of focus, and (4)
dentate granule neurons must have been located in the outer one-
half of the granule cell layer in DG. Cells chosen for analyses had
to be well impregnated, clearly distinguishable from adjacent cells
and have continuous unbroken dendrites. Spines were counted
under oil (X100), using light microscopy (Axostar Plus equipped
with Axio-Cam MRc, Zeiss), and the entire visible dendritic length
measured by Imaging computer program (Axio-Vision, Zeiss).
Spine density was calculated referring to the length of the dendrite.
Measurement of spinal cord TNF-a and IL-1b levels
Portions of spinal cord tissues, collected at 24 hours after SCI,
were homogenized as previously described in PBS containing
2 mmol/L of phenyl-methyl sulfonyl fluoride (PMSF, Sigma
Chemical Co.) and tissue TNF-a and IL-1b levels were evaluated.
The assay was carried out by using a colorimetric, commercial kit
(Calbiochem-Novabiochem Corporation, USA) according to the
manufacturer instructions. All TNF-a and IL-1b determinations
were performed in duplicate serial dilutions.
Grading of motor disturbance
The motor function of mice subjected to compression trauma
was assessed once a day for 20 days after injury. Recovery from
motor disturbance was graded using the Basso Mouse Scale [33].
CNS drug penetration: In vitro Parallel artificial
membrane permeability assay (PAMPA)
Prediction of the brain penetration was evaluated using a parallel
artificial membrane permeability assay (PAMPA) [34]. Ten commer-
cial drugs, phosphate buffer saline solution at pH 7.4 (PBS), DMSO
and dodecane were purchased from Sigma, Acros organics, Aldrich
and Fluka. The porcine polar brain lipid (PBL) (catalog no. 141101)
was from Avanti Polar Lipids. The donor plate was a 96-well filtrate
plate (MultiscreenH I PS t e r i l eP l a t eP D V Fm e m b r a n e ,p o r es i z ei s
0.45 mM, catalog no. MAIPS4510) and the acceptor plate was an
indented 96-well plate (MultiscreenH, catalog no. MAMCS9610 from
Millipore). Filter PDVF membrane units (diameter 30 mm, pore size
0.45 mm) from Symta were used to filtered the samples. A 96-well
plate UV reader (Thermoscientific, Multiskan spectrum) was used for
the UV measurements. Test compounds (3–5 mg of Cafeine,
Enoxacine, Hydrocortisone, Desipramine, Ofloxacine, Piroxicam,
Testosterone, 12 mg of Promazine and 25 mg of Verapamile and
Atenolol) were dissolved in DMSO (250 mL). 25 microlitres of this
compound stock solution was taken and 225 mLo fD M S Oa n d
4750 mL of PBS pH=7.4 buffer were added to reach 5% of DMSO
concentration in the experiment. This solution was filtered. The
acceptor 96-well microplate was filled with 180 mLo fP B S / D M S O
(95/5). The donor 96-well plate was coated with 4 mLo fp o r c i n eb r a i n
lipid in dodecane (20 mg mL
21) and after 5 minutes, 180 mLo fe a c h
compound solution was added. 1–2 mg of every compound to be
determined their ability to pass the brain barrier were dissolved in
250 mL of DMSO and 4750 mL of PBS pH=7.4 buffer, filtered and
then added to the donor 96-well plate. Then the donor plate was
carefully put on the acceptor plate to form a ‘‘sandwich’’, which was
left undisturbed for 4 h at 25uC. During this time the compounds
diffused from the donor plate throu g ht h eb r a i nl i p i dm e m b r a n ei n t o
the acceptor plate. After incubation, the donor plate was removed.
The concentration of compounds and commercial drugs in the
acceptor and the donor wells was determined by UV plate reader.
Every sample was analyzed at three to five wavelengths, in 3 wells and
in three independent runs. Results are given as the mean [standard
deviation (SD)] and the average of the three runs is reported. 10
quality control compounds (previously mentioned) of known BBB
permeability were included in each experiment to validate the analysis
set.
Materials
All compounds were obtained from Sigma-Aldrich Company
Ltd. (Milan, Italy). All other chemicals were of the highest
commercial grade available. All stock solutions were prepared in
non-pyrogenic saline (0.9% NaCl; Baxter, Italy, UK). S14 and
VP1.15 were synthesized in the Instituto de Quimica Medica
following described procedures.
Statistical evaluation
All values in the figures and text are expressed as mean 6
standard error of the mean (SEM) of N observations. For the in
vivo studies N represents the number of animals studied. In the
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figures shown are representative of at least three experiments
performed on different experimental days. The results were
analyzed by one-way ANOVA followed by a Bonferroni post-hoc
test for multiple comparisons. A p-value of less than 0.05 was
considered significant. BBB scale data were analyzed by the
Mann-Whitney test and considered significant when p- value was
,0.05.
Results
S14 and VP 1.15 reduce the severity of spinal cord trauma
The severity of the trauma at the level of the perilesional area,
that assessed the presence of edema as well as alteration of the
white matter, was evaluated at 24 h after injury. A significant
damage to the spinal cord was observed in the spinal cord tissue
from SCI mice when compared with sham-operated mice
(Figures 2b,b1 and 2a,a1 respectively, see histological score
Figure 2e). Notably, a significant protection against the spinal
cord injury was observed in mice group treated with VP1.15 and
S14 (Figures 2c,c1 and 2d,d1 respectively, see histological score
Figure 2e). Alteration of the morphology of neurons and glia cells
were observed by Golgi staining that selectively impregnates single
neurons with silver chromate. A significant alteration of morphol-
ogy was observed in the spinal cord tissue from SCI mice when
compared with sham-operated mice (Figures 1c and 1d respec-
tively). A protection against alteration of neuron’s morphology was
observed in mice group treated with VP1.15 and S14 (Figures 1e,
and 1f respectively).
Moreover to evaluate if histological damage to the spinal cord
was associated with a loss of motor function, the modified BMS
hind limb locomotor rating scale score was evaluated. While motor
function was only slightly impaired in sham mice, mice subjected
to SCI had significant deficits in hind limb movement (Figure 3).
VP1.15 and S14 treatment ameliorated the functional deficits
induced by SCI (Figure 3).
Effect of VP 1.15 and S14 on IkB-a degradation
By western blot analysis we evaluated IkB-a degradation, to
investigate the cellular mechanisms by which treatment with
VP1.15 and S14 may attenuate the development of SCI.
A basal level of IkB-a was detected in the spinal cord from
sham-operated animals (Figures 4a, a1 and 4b, b1), whereas IkB-a
levels were substantially reduced in SCI mice. Administration of
VP1.15 (Figure 4a, a1) and S14 (Figure 4b, b1) prevented the SCI-
induced IkB-a degradation.
Effect of VP 1.15 and S14 on expression of TNF-a and
IL-1b and neutrophil infiltration after SCI
The histological pattern of spinal cord injury appeared to be
correlated with the influx of leukocytes into the spinal cord.
Therefore, we investigated the effect of VP1.15 and S14 on the
neutrophil infiltration by measuring tissue MPO activity
(Figure 5c). MPO activity was significantly elevated in the spinal
cord at 24 h after injury in mice subjected to SCI when compared
with Sham-operated mice (Figure 5c). In VP1.15 and S14 treated
mice, the MPO activity in the spinal cord at 24 h after injury was
significantly attenuated in comparison to that observed in SCI
controls (Figure 5c).
To test whether PDE7 inhibitors modulates the inflammatory
process trough the regulation of secretion of pro-inflammatory
cytokines, we analysed the spinal cord levels of TNF-a and IL-1b.
A substantial increase in TNF-a (Figure 5a) and IL-1b (Figure 5b)
production was found in spinal cord tissue collected from SCI
mice at 24 h. Spinal cord levels of TNF-a and IL-1b were
significantly attenuated by the VP1.15 and S14 treatment
(Figure 5a and 5b respectively).
PDE7 inhibitors modulate the expression of TNF-a and
IL-1b after SCI
Moreover, spinal cord sections were taken at 24 h after SCI to
determine the immunohistological staining for TNF-a and IL-1b
expression. There was no staining for TNF-a Figure 6a) and IL-1b
(Figure 6e) in spinal cord obtained from the sham mice. A
substantial increase in TNF-a (Figure 6b, see densitometry analysis
Figure 6i) and IL-1b (Figure 6f, see densitometry analysis Figure 6i)
expression was found in inflammatory cells in the white and gray
matter of the spinal cord tissues collected from SCI mice 24 hours
after SCI. Spinal cord expression of TNF-a and IL-1b were
significantly attenuated in mice treated with VP1.15 (Figure 6d
and 6h respectively, see densitometry analysis Figure 6i) and S14
(Figure 6c and 6g respectively, see densitometry analysis Figure 6i)
in comparison to SCI animals.
Effect of VP1.15 and S14 on COX-2 expression and on
activation of MAPK signal transduction pathway
As phosphorylation of ERK1/2 results in expression of genes,
such as that encoding for COX-2, mediating the inflammatory
responses characteristic of SCI. The expression of this enzyme and
ERK1/2 phosphorylation in homogenates of spinal cord tissues
was investigated by western blot and immunohistochemical
analysis at 24 h after SCI.
Spinal cord sections were taken at 24 h after SCI to determine
the immunohistological staining for COX-2 expression. There was
no staining for COX-2 in spinal cord obtained from the sham
mice (Figure 7a, see densitometry analysis Figure 7e). A substantial
increase in COX-2 expression was found in inflammatory cells of
the spinal cord tissues collected from SCI mice 24 hours after SCI
(Figure 7b, see densitometry analysis Figure 7e) Spinal cord
expression of COX-2 were significantly attenuated in mice treated
with VP1.15 (Figure 7c, see densitometry analysis Figure 7e) and
S14 (Figure 7d, see densitometry analysis Figure 7e) in comparison
to SCI animals.
To investigate whether the increase in COX-2 expression,
observed in our experimental conditions, corresponded to an
activation of signal transduction pathways involved in the
regulation of COX-2 expression, we analyzed the activation of
MAPK pathways in particular the phosphorylation of ERK1/2
24 h after SCI by western blot analysis. As shown in Figure 6,
pERK1/2 levels were significantly increased in the spinal cord
tissues of SCI mice group (Figures 7f, 7f1 and 7g, 7g1). Treatment
with VP 1.15 (Figures 7f, 7f1) and S14 (Figures 7g, 7g1)
significantly reduced the level of pERK1/2.
Effects of PDE7 inhibitors on iNOS formation after SCI
Twenty-four hours after SCI, iNOS, a specific marker of
oxidative stress, was measured by immunohistochemical analysis
in the spinal cord sections. Spinal cord sections from sham-operated
mice did not stain for iNOS (Figure 8a, see densitometric analysis
Figure 8e), whereas spinal cord sections obtained from SCI mice
exhibited positive staining for iNOS (Figure 8 b, see densitometric
analysis Figure 8e). The positive staining was mainly localized in
inflammatory cells in the white and gray matter of the spinal cord
tissues. VP 1.15 (Figure 8c, seedensitometric analysis Figure 8e) and
S14 (Figure 8d, see densitometric analysis Figure 8e) treatment
reduced the degree of positive staining for iNOS in the spinal cord.
PDE7 Inhibitors as New Drugs for SCI
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damage to the spinal cord, from SCI operated mice at the perilesional area, was assessed by the presence of edema as well as alteration of the white
matter 24 h after injury (b and b1, see histological score e). Notably, a significant protection from SCI damage was observed in the tissue collected
from VP1.15 and S14 treated mice (c, c1 and d, d1 respectively, see histological score e). The histological score (e) was made by an independent
observer. wm: White matter; gm: gray matter. This figure is representative of at least 3 experiments performed on different experimental days. Values
shown are mean 6 s.e. mean of 10 mice for each group. *p,0.01 vs. Sham. up,0.01 vs. SCI+vehicle.
doi:10.1371/journal.pone.0015937.g002
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and Bcl-2
To test whether spinal cord damage was associated to cell death
by apoptosis, we measured the levels of Bax and Bcl-2 expression.
At 24 h after SCI, the appearance of pro-apoptic protein Bax, in
spinal cord homogenates was investigated by Western blot. Bax
levels were appreciably increased in the spinal cord from mice
subjected to SCI (Figures 9a, 9a1 and 9b, 9b1). On the contrary,
VP 1.15(Figures 9a, 9a1) and S14 (Figures 9b, 9b1) treatment
prevented the SCI-induced Bax expression.
Bcl-2 expression was also analyzed by Western blot in
homogenates from spinal cord of each mouse. A basal level of
Bcl-2 expression was detected in spinal cord from sham-operated
mice (Figures 10a, 10a1 and 10b, 10b1). Twenty-four hours after
SCI, the Bcl-2 expression was significantly reduced in spinal cord
from SCI mice (Figures 10a, 10a1 and 10b, 10b1). Treatment of
mice with VP 1.15 (Figures 10a, 10a1) and S14 (Figures 10b, 10b1)
significantly blunted the SCI-induced inhibition of anti-apoptotic
protein expression.
S14 and VP1.15 penetrate into the brain in an
experimental model
One of the main obstacles for the treatment of the diseases of
the central nervous system (CNS) is the drug’s penetration into the
blood-brain barrier (BBB) at therapeutic concentrations. The BBB
is a complex interface between blood and the central nervous
system that strictly controls the exchanges between the blood and
brain compartments [35]. This barrier is composed by endothelial
cells with tight junctions that protect the brain from endogenous
materials which could damage the brain tissues. [36] The majority
of CNS drugs enter the brain by transcellular passive diffusion, due
to the tight junction structure and limited transport pathways. In
early drug discovery stage, evaluation of ADME (Absorption,
Distribution, Metabolism, and Excretion) properties is of crucial
importance to reduce attrition in development process. PAMPA
assay is a high throughput technique developed to predict passive
permeability through biological membranes. In order to explore
Figure 3. Effect of VP1.15 and S14 treatment on hind limb
motor disturbance after spinal cord injury. The degree of motor
disturbance was assessed every day until 10 days after SCI, by using the
Basso mouse scale (BMS) open-field score. Treatment with VP1.15 and
S14 reduces the motor disturbance after SCI. Values shown are mean 6
s.e. mean of 10 mice for each group. *p,0.01 vs. Sham. up,0.01 vs.
SCI+vehicle.
doi:10.1371/journal.pone.0015937.g003
Figure 4. Effects of VP1.15 and S14 treatment on IkB-a degradation. By Western Blot analysis, a basal level of IkB-a was detected in the
spinal cord from sham-operated animals, whereas IkB-a levels were substantially reduced in SCI mice (a, a1 and b,b1). VP 1.15 and S14 treatment
prevented the SCI-induced IkB-a degradation (a, a1 and b,b1 respectively). A representative blot of lysates obtained from each group is shown, and
densitometry analysis of all animals is reported. The relative expression of the protein bands from three separated experiments was standardized for
densitometry analysis *P,0.01 vs. Sham; uP,0.01 vs. SCI.
doi:10.1371/journal.pone.0015937.g004
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used the PAMPA-BBB method described by Di et al [34] which
employed a brain lipid porcine membrane. The in vitro
permeabilities (Pe) of commercial drugs through lipid membrane
extract together with compounds S145 and VP1.15 were
determined and described in Figure 11b. An assay validation
was made comparing the reported permeabilities values of
commercial drugs with the experimental data obtained employing
this methodology. A good correlation between experimental-
described values was obtained (Pe (exptl)=1.0369, Pe
(bibl)=20.1354, R
2=0.939, see Figure 11a). From this equation
and following the pattern established in the literature for BBB
permeation prediction [37] we could classify compounds as CNS +
when they present a permeability .4.01610
26 cm s
21. Based on
these results we can consider that compounds S14 and VP1.15
that are able to cross the BBB by passive permeation (Figure 11b).
Discussion
SCI induces lifetimedisability, and nosuitable therapyis available
to treat victims or to minimize their suffering. We report here that
the pharmacological inhibition of PDE7 isoenzyme using two new
chemicallydiverse small moleculeinhibitors exertsa protective effect
against the pathological changes caused by SCI. Thus, we propose
that PDE7 contributes to the pathophisiology of SCI.
SCI in mice induced by the application of vascular clips (force of
24 g) to the dura via a four-level T5-T8 laminectomy, resulted in
severe trauma characterized by edema, neutrophil infiltration and
loss of myelin in lateral and dorsal funiculi. This histological
damage was associated to the loss of motor function. SCI induced
an inflammatory response in the spinal cord characterized by
increased IkB-degradation, production of a range of inflammatory
mediators such iNOS, and COX-2 and increased MPO activity.
Treatment of the mice with our new PDE7 inhibitors named S14
and VP1.15, derivatives of quinazoline and 5-imino-1,2,4-
thiadiazole scaffolds respectively, significantly reduced the degree
of 1) spinal cord inflammation and tissue injury (histological score);
2) neutrophil infiltration (myeloperoxidase activity); 3) inducible
nitric-oxide synthase, and cyclooxygenase-2 expression; and 4) and
apoptosis (Bax and Bcl-2 expression). What is then the mechanism
by which inhibition of PDE7 decrease the secondary inflammation
caused by SCI? First, we have been shown previously that S14 and
VP1.15 inhibit PDE7 [25,26], one of the isoenzymes of PDEs
family responsible for the degradation of cAMP and selectively
expressed on macrophagues and brain [38,39]. We have also
previously shown that S14 and VP1.15 treatment of human
neuroblastoma and rat macrophagues cell lines, SH-SY5Y and
D10.G4.1 respectively, with these compounds lead to an increase
in intracellular cAMP level [23b, 23c]. It is recently shown that
elevation of endothelial cell cAMP levels inhibits degradation of
Figure 5. Effect of VP1.15 and S14 on TNF-a and IL-1b release and on MPO activity. A substantial increase in TNF-a (a) and IL-1b (b)
production was found in spinal cord tissue collected from SCI mice at 24 h. Spinal cord levels of TNF-a and IL-1b were significantly attenuated by the
VP 1.15 and S14 treatment (a, b respectively). Moreover, MPO activity in spinal cord of untreated SCI-operated mice was significantly increased at 24 h
after the damage in comparison to sham mice (c). Treatment with VP 1.15 and S14 significantly reduced the SCI-induced increase in MPO activity (c).
Data are means 6S.E. mean of 10 mice for each group. *p,0.01 vs sham, up,. 0.01 vs SCI.
doi:10.1371/journal.pone.0015937.g005
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determine the immunohistological staining for TNF-a and IL-1b expression. A substantial increase in TNF-a (b) and IL-1b (f) expression was found in
inflammatory cells of the spinal cord tissues from SCI mice at 24
th hour after SCI. Spinal cord levels of TNF-a and IL-1b expression were significantly
attenuated in VP 1.15 (d,h respectively) and S14 (c, g respectively) treated mice in comparison to SCI animals. Densitometry analysis of
immunocytochemistry photographs (n=5 photos from each sample collected from all mice in each experimental group) for TNF-a and IL-1b (i) from
spinal cord tissues was assessed. The assay was carried out by using Optilab Graftek software on a Macintosh personal computer (CPU G3-266). Data
are expressed as % of total tissue area. This figure is representative of at least 3 experiments performed on different experimental days. *p,0.01 vs.
Sham. up,0.01 vs SCI+vehicle. ND: not detectable.
doi:10.1371/journal.pone.0015937.g006
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we have shown a basal level of IkB-a in the spinal cord from sham-
operated animals, whereas IkB-a levels were subtantially reduced
in SCI mice. The prevention of SCI-induced IkB-a degradation
observed in mice treated with S14 and VP 1.15 should be then
attributed to the increase on cAMP.
The second possible mechanism by which S14 and VP1.15 may
protect the spinal cord is as an anti-inflammatory one. We found
that levels of TNF-a and IL-1b had significantly decreased in the
S14 and VP1.15 treated groups. Primary injury to the adult spinal
cord is irreversible, whereas secondary degeneration is delayed and
therefore amenable to intervention. Accordingly, several studies
have shown that therapies targeting various factors involved in the
secondarydegenerationcascade lead totissue sparing andimproved
behavioral outcomes in spinal cord-injured animals [41,42,43,44].
In this report we demonstrate that VP1.15 and S14, PDE7
inhibitors, exerts beneficial effects in a mice model of spinal cord
injury. We demonstrate here that SCI resulted in edema and loss of
myelin in lateral and dorsal funiculi. This histological damage was
associated to the loss of motor function. SCI induced an
inflammatory response in the spinal cord, characterized by
increased IkB-a degradation, enhanced NF-kB activation, ampli-
fied expression of pro-inflammatory mediators, pro-inflammatory
cytokines andnitrotyrosineandincreased MPOactivity.Ourresults
show that VP1.15 and S14 reduced (1) the degree of spinal cord
damage, (2) neutrophils infiltration, (3) IkB-a degradation, (4)
nitrotyrosine formation, (5) pro-inflammatory cytokines production,
and (6) apoptosis as Bax and Bcl-2 expression.
The ERK1/2 and p38 MAPK signaling pathways have been
found to be involved in microglial/macrophage activation
[45,46,47]. Previous studies show that the expression of activated
ERK1/2 and p38 MAPK in microglia/macrophages may play a
key role in production of CNS inflammatory cytokines and free
radicals, such as NO [48,49]. In the present study, we have
observed an increase of phosphorylated MAPKs (ERK, p38, and
JNK) in the spinal cord tissues at 24 h after SCI which are
significantly reduced by the treatment with VP1.15 and S14.
Recent evidence suggests that the activation of NF-kB may also be
Figure 7. Effect of VP 1.15 and S14 on activated kinases. At 24 h after injury we assessed, by immunohistological staining, an increase of Cox-
2 expression. A substantial increase in Cox-2 expression was found in spinal cord tissue collected from SCI mice group (b),whereas treatment with
VP1.15 (c) and S14 (d) reduced markedly a staining for Cox-2. Densitometry analysis of immunocytochemistry photographs (n=5 photos from each
sample collected from all mice in each experimental group) for Cox-2 (e) from spinal cord tissues was assessed. The assay was carried out by using
Optilab Graftek software on a Macintosh personal computer (CPU G3-266). Data are expressed as % of total tissue area. This figure is representative of
at least 3 experiments performed on different experimental days. *p,0.01 vs. Sham. up,0.01 vs SCI+vehicle. ND: not detectable. SCI caused an
increase of the ERK1/2 phosphorylation in vehicle-treated mice (f, f1 and g, g1). The treatment with VP1.15 (f, f1) and S14 (g, g1) reduced pERK1/2
levels. Densitometric analysis of protein expression represents the mean 6 s.e.mean of 10 spinal cord tissues. Data were normalized on the basis of
ERK-2 levels. *P,0.01 vs sham; uP,0.05 vs SCI + vehicle.
doi:10.1371/journal.pone.0015937.g007
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various experimental evidence have clearly suggested that NF-kB
plays a central role in the regulation of many genes responsible for
the generation of mediators or proteins in secondary inflammation
associated with SCI [51]. NF-kB is normally sequestered in the
cytoplasm, bound to regulatory proteins IkBs. In response to a
wide range of stimuli including oxidative stress, infection, hypoxia,
extracellular signals, and inflammation, IkB is phosphorylated by
the enzyme IkB kinase [52]. The net result is the release of the NF-
kB dimer, which is then free to translocate into the nucleus. The
exact mechanisms by which PDE7 inhibitors suppress NF-kB
activation in inflammation are not known. We report here that
SCI caused a significant increase in the phosphorylation of Ser536
on p65 in the spinal cord tissues at 24 h, whereas S14 and VP1.15
treatment significantly reduced this phosphorylation. Moreover,
we also demonstrate that PDE7 inhibitors inhibited the IkB-a
degradation as well as the NF-kB translocation. Taken together,
the balance between pro-inflammatory and pro-survival roles of
NF-kB may depend on the phosphorylation status of p65, and
MAPK play a central role in this process. In this regard, recently it
has been demonstrated that the elevation of cell cAMP levels,
inhibits NF-kB activation by targeting p38 mitogen activated
protein kinases (MAPK) [53]. Thus, the activity of PDE7
inhibitors on the cAMP levels might account for its effect on
NF-kB activation, since have been showed that cAMP also
activates protein kinase A, which inhibits NF-kB [54].
NF-kB plays a central role in the regulation of many genes
responsible for the generation of mediators or proteins in
inflammation. These include the genes for TNF-a, IL-1b, iNOS
and COX-2, to name but a few [55]. In this regard, it has been
well demonstrated that in SCI the expression of pro-inflammatory
cytokines (TNF-a and IL-1b) at the site of injury regulates the
precise cellular events after SCI [56,57]. We have clearly
confirmed a significant increase in TNF-a and IL-1b in SCI.
On the contrary, no significant expression of TNF-a and IL-1b
was observed in the spinal cord sections obtained from SCI-
Figure 8. Effects of PDE7 inhibitors on iNOS expression. iNOS expression was evaluated by immunohystochemical analysis in the spinal cord
section 24 h after SCI. Spinal cord section from sham-operated mice did not stain for iNOS (a), whereas spinal cord section obtained from SCI-
operated mice exhibited positive staining for iNOS (b) mainly localized in various inflammatory cells in the grey matter. VP 1.15 and S14 treatment (c,
d respectively) reduced the degree for positive staining for iNOS in the spinal cord tissue. Densitometry analysis of immunocytochemistry
photographs (n=5 photos from each sample collected from all mice in each experimental group) for iNOS (e) from spinal cord tissues was assessed.
The assay was carried out by using Optilab Graftek software on a Macintosh personal computer (CPU G3-266). Data are expressed as % of total tissue
area. ND: not detectable. This figure is representative of at least 3 experiments performed on different experimental days. *p,0.01 vs Sham. up,0.01
vs SCI+vehicle.
doi:10.1371/journal.pone.0015937.g008
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and b, b1). On the contrary, VP1.15 (a, a1) and S14 (b, b1) treatment prevented the SCI-induced Bax expression. The relative expression of the protein
bands was standardized for densitometric analysis to b-actin levels, and reported in panel a, a1 and b, b1 are expressed as mean 6 s.e.m. from n=5/6
spinal cord for each group. *P,0.01 vs sham, uP,0.01 vs SCI+vehicle.
doi:10.1371/journal.pone.0015937.g009
Figure 10. Western blot analysis for Bcl-2. Moreover, a basal level of Bcl-2 expression was detected in spinal cord from sham-operated mice (a,
a1 and b, b1). Twenty-four hours after SCI, Bcl-2 expression was significantly reduced in spinal cord from SCI mice (a, a1 and b, b1). Treatment with VP
1.15 (a, a1) and S14 (b, b1) significantly reduced the SCI-induced inhibition of Bcl-2 expression. The relative expression of the protein bands was
standardized for densitometric analysis to b-actin levels, and reported in panel a, a1 and b, b1 are expressed as mean 6 s.e.m. from n=5/6 spinal cord
for each group. *P,0.01vs sham, uP,0.01 vs SCI+vehicle.
doi:10.1371/journal.pone.0015937.g010
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suggesting that PDE7 pathway play an important role in the
regulation of proinflammatory cytokines. This observation is in
agreement with previous studies in which have been demonstrated
that S14 and VP 1.15 treatment reduced the inflammatory
activation of primary cell cultures of neurones, microglia and
astrocytes treated with lipopolisacharide (LPS) measured by the
decrease on nitrite production.
Several studies suggest that glial cells in neurodegenerative
diseases (i.e., Alzheimer’s disease) are affected more than neurons
by apoptotic cell death [58,59]. Apoptosis is an important
mediator of secondary damage after SCI [60,61]. It incurs its
affects through at least two phases: an initial phase, in which
apoptosis accompanies necrosis in the degeneration of multiple cell
types and a later phase, which is predominantly confined to white
matter and involves oligodendrocytes and microglia [62].
Chronologically, apoptosis initially occurs 6 hours post-injury at
the lesion center and last for several days associated with the
steadily increased number of apoptotic cells in this.
Various studies have postulated that preserving Bax, a pro-
apoptotic gene, plays an important role in developmental cell death
[63] and in CNS injury [64]. Similarly, it has been shown that the
administration of Bcl-xL fusion protein (Bcl-xL FP), (Bcl-2 is the
most expressed antiapoptotic molecule in adult central nervous
system) into injured spinal cords significantly increased neuronal
survival, suggesting that SCI-induced changes in Bcl-xL contribute
considerably to neuronal death [65]. Based on these evidences, we
have identified in SCI proapoptotic transcriptional changes,
including upregulation of proapoptotic Bax and down regulation
ofantiapoptoticBcl-2,byimmunohystochemicalstaining.Wereport
in the present study that the pharmacological inhibition of PDE7
pathway by VP1.15 and S14 in SCI experimental model documents
features of apoptotic cell death after SCI, suggesting that protection
from apoptosis may be a prerequisite for regenerative approaches to
SCI. In particular, we demonstrated that the treatment with VP1.15
and S14 reduced Bax expression; while on the contrary, Bcl-2
expressed much more in mice treated with VP1.15 and S14. A lot of
number of studies has linked apoptosis to SCI.
However is not possible to exclude that anti- apoptotic effect
observed after VP1.15 and S14 treatment it may be partially
dependentonthe attenuation oftheinflammatory-induced damage.
Further studies are needed in order to clarify these mechanisms.
Finally, we have shown that our two new drugs VP1.15 and S14
are able to cross the blood brain barrier which increase the value
of these compounds as potential candidates for further pharma-
cological development.
In summary, we have demonstrated that VP1.15 and S14
treatment significantly reduced the SCI-induced spinal cord tissues
alteration as well as improve the motor function. The results of the
present study enhance our understanding of the role of PDE7
pathway in the pathophysiology of spinal cord cell and tissue
injury following trauma, implying that inhibitors of the activity of
PDE7 pathway may be useful in the therapy of spinal cord injury,
trauma and inflammation.
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Figure 11. PAMPA-BBB assay results. A linear correlation between experimental and reported permeability of selected commercial drugs using
the experimental conditions described in the PAMPA-BBB assay methodology was found (10a). The permeability (Pe 10
26 cm s
21) value obtained in
the PAMPA-BBB assay for the 10 commercial drugs and used in the experiment validation, were reported in Figure 10b. The Pe obtained in the same
experimental conditions for compounds S14 and VP1.15 predict their penetration in the CNS.
doi:10.1371/journal.pone.0015937.g011
PDE7 Inhibitors as New Drugs for SCI
PLoS ONE | www.plosone.org 13 January 2011 | Volume 6 | Issue 1 | e15937References
1. Maegele M, Gregor S, Steinhausen E, Bouillon B, Heiss MM, et al. (2005) The
long-distance tertiary air transfer and care of tsunami victims: injury pattern and
microbiological and psychological aspects. Crit Care Med 33: 1136–1140.
2. Bartholdi D, Schwab ME (1995) Methylprednisolone inhibits early inflamma-
tory processes but not ischemic cell death after experimental spinal cord lesion in
the rat. Brain Res 672: 177–186.
3. Levy ML, Chen JC, Amar AP, Yamada S, Togo K, et al. (1999) Virtual
endoscopic environments in modern neurosurgical practice. Neurosurg Focus 6:
e11.
4. Carlson SL, Parrish ME, Springer JE, Doty K, Dossett L (1998) Acute
inflammatory response in spinal cord following impact injury. Exp Neurol 151:
77–88.
5. de Castro R, Hughes MG, Xu GY, Clifton C, Calingasan NY, et al. (2004)
Evidence that infiltrating neutrophils do not release reactive oxygen species in
the site of spinal cord injury. Exp Neurol 190: 414–424.
6. Popovich PG, Wei P, Stokes BT (1997) Cellular inflammatory response after
spinal cord injury in Sprague-Dawley and Lewis rats. J Comp Neurol 377:
443–464.
7. Profyris C, Cheema SS, Zang D, Azari MF, Boyle K, et al. (2004) Degenerative
and regenerative mechanisms governing spinal cord injury. Neurobiol Dis 15:
415–436.
8. Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide
phosphodiesterases: essential components in cyclic nucleotide signaling. Annu
Rev Biochem 76: 481–511.
9. Essayan DM (1999) Cyclic nucleotide phosphodiesterase (PDE) inhibitors and
immunomodulation. Biochem Pharmacol 57: 965–973.
10. Allison AC (2000) Immunosuppressive drugs: the first 50 years and a glance
forward. Immunopharmacology 47: 63–83.
11. Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new
target for the development of specific therapeutic agents. Pharmacol Ther 109:
366–398.
12. Dyke HJ, Montana JG (2002) Update on the therapeutic potential of PDE4
inhibitors. Expert Opin Investig Drugs 11: 1–13.
13. Spina D (2003) Phosphodiesterase-4 inhibitors in the treatment of inflammatory
lung disease. Drugs 63: 2575–2594.
14. Menniti FS, Faraci WS, Schmidt CJ (2006) Phosphodiesterases in the CNS:
targets for drug development. Nat Rev Drug Discov 5: 660–670.
15. Giembycz MA, Corrigan CJ, Seybold J, Newton R, Barnes PJ (1996)
Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+
and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis
of interleukin-2. Br J Pharmacol 118: 1945–1958.
16. Manning CD, Burman M, Christensen SB, Cieslinski LB, Essayan DM, et al.
(1999) Suppression of human inflammatory cell function by subtype-selective
PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.
Br J Pharmacol 128: 1393–1398.
17. Houslay MD, Schafer P, Zhang KY (2005) Keynote review: phosphodiesterase-4
as a therapeutic target. Drug Discov Today 10: 1503–1519.
18. Giembycz MA (2005) Life after PDE4: overcoming adverse events with dual-
specificity phosphodiesterase inhibitors. Curr Opin Pharmacol 5: 238–244.
19. Li L, Yee C, Beavo JA (1999) CD3- and CD28-dependent induction of PDE7
required for T cell activation. Science 283: 848–851.
20. Nakata A, Ogawa K, Sasaki T, Koyama N, Wada K, et al. (2002) Potential role
of phosphodiesterase 7 in human T cell function: comparative effects of two
phosphodiesterase inhibitors. Clin Exp Immunol 128: 460–466.
21. Yang G, McIntyre KW, Townsend RM, Shen HH, Pitts WJ, et al. (2003)
Phosphodiesterase 7A-deficient mice have functional T cells. J Immunol 171:
6414–6420.
22. Castro A, Jerez MJ, Gil C, Martinez A (2005) Cyclic nucleotide phosphodies-
terases and their role in immunomodulatory responses: advances in the
development of specific phosphodiesterase inhibitors. Med Res Rev 25:
229–244.
23. Gil C, Perez DI, Martinez A (2008) PDE7 inhibitors as new drugs for
neurological and inflammatory disorders. Exp Opin Ther Patents 18:
1127–1139.
24. Castro A, Jerez MJ, Gil C, Calderon F, Domenech T, et al. (2008) CODES, a
novel procedure for ligand-based virtual screening: PDE7 inhibitors as an
application example. Eur J Med Chem 43: 1349–1359.
25. Castano T, Wang H, Campillo NE, Ballester S, Gonzalez-Garcia C, et al. (2009)
Synthesis, structural analysis, and biological evaluation of thioxoquinazoline
derivatives as phosphodiesterase 7 inhibitors. ChemMedChem 4: 866–876.
26. Redondo M, Perez VP, Campillo N, Cadavid I, Loza I, et al. (2009) Neuronal
Networks for the Discovery of PDE7 Inhibitors Active on CNS Diseases. Drugs
of the Future 34(SuppA): 142.
27. Martinez AC, Palomo V, Perez DI, Perez C, Perez-Castillo A, et al. (2009) 5-
imino substituted 1,2,4-thiadiazoles useful for the treatment of neurodegener-
ative diseases.
28. Rivlin AS, Tator CH (1978) Effect of duration of acute spinal cord compression
in a new acute cord injury model in the rat. Surg Neurol 10: 38–43.
29. Morales-Garcia JA, Alonso-Gil S, Gil C, Martinez A, Perez-Castillo A (2009)
Selective PDE7 inhibition prevents progressive dopamine neuron degeneration
in a rat model of Parkinson disease. J Neurochem 110(Supp2): 119.
30. Mullane K (1989) Neutrophil-platelet interactions and post-ischemic myocardial
injury. Prog Clin Biol Res 301: 39–51.
31. Bethea JR, Castro M, Keane RW, Lee TT, Dietrich WD, et al. (1998)
Traumatic spinal cord injury induces nuclear factor-kappaB activation.
J Neurosci 18: 3251–3260.
32. Sirin BH, Ortac R, Cerrahoglu M, Saribulbul O, Baltalarli A, et al. (2002)
Rendeci, Ischaemic preconditioning reduces spinal cord injury in transient
ischaemia. Acta Cardiol 57: 279–285.
33. Basso DM, Fisher LC, Anderson AJ, Jakeman LB, McTigue DM, et al. (2006)
Basso Mouse Scale for locomotion detects differences in recovery after spinal
cord injury in five common mouse strains. J Neurotrauma 23: 635–659.
34. Di L, Kerns EH, Fan K, McConnell OJ, Carter GT (2003) High throughput
artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem
38: 223–232.
35. Cardoso FL, Brites D, Brito MA (2010) Looking at the blood-brain barrier:
molecular anatomy and possible investigation approaches. Brain Res Rev 64:
328–363.
36. van Asperen J, Mayer U, van Tellingen O, Beijnen JH (1997) The functional
role of P-glycoprotein in the blood-brain barrier. J Pharm Sci 86: 881–884.
37. Crivori P, Cruciani G, Carrupt PA, Testa B (2000) Predicting blood-brain
barrier permeation from three-dimensional molecular structure. J Med Chem
43: 2204–2216.
38. Reyes-Irisarri E, Perez-Torres S, Mengod G (2005) Neuronal expression of
cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neuroscience 132:
1173–1185.
39. Lee R, Wolda S, Moon E, Esselstyn J, Hertel C, et al. (2002) PDE7A is expressed
in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP.
Cell Signal 14: 277–284.
40. Hong G, Zhang B, Harbrecht BG (2010) Cyclic AMP inhibits IL-1beta plus
IFNgamma-induced NF-kappaB translocation in hepatocytes by a PKA
independent mechanism. J Surg Res 159: 565–571.
41. Bao F, DeWitt DS, Prough DS, Liu D (2003) Peroxynitrite generated in the rat
spinal cord induces oxidation and nitration of proteins: reduction by Mn (III)
tetrakis (4-benzoic acid) porphyrin. J Neurosci Res 71: 220–227.
42. Cuzzocrea S, Genovese T, Mazzon E, Crisafulli C, Min W, et al. (2006)
Poly(ADP-ribose) glycohydrolase activity mediates post-traumatic inflammatory
reaction after experimental spinal cord trauma. J Pharmacol Exp Ther 319:
127–138.
43. Genovese T, Mazzon E, Mariotto S, Menegazzi M, Cardali S, et al. (2006)
Modulation of nitric oxide homeostasis in a mouse model of spinal cord injury.
J Neurosurg Spine 4: 145–153.
44. Glaser J, Gonzalez R, Sadr E, Keirstead HS (2006) Neutralization of the
chemokine CXCL10 reduces apoptosis and increases axon sprouting after spinal
cord injury. J Neurosci Res 84: 724–734.
45. Bhat NR, Zhang P, Lee JC, Hogan EL (1998) Extracellular signal-regulated
kinase and p38 subgroups of mitogen-activated protein kinases regulate
inducible nitric oxide synthase and tumor necrosis factor-alpha gene expression
in endotoxin-stimulated primary glial cultures. J Neurosci 18: 1633–1641.
46. Choi SH, Joe EH, Kim SU, Jin BK (2003) Thrombin-induced microglial
activation produces degeneration of nigral dopaminergic neurons in vivo.
J Neurosci 23: 5877–5886.
47. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J (2001)
Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity
by inhibiting activation and proliferation of microglia. J Neurosci 21:
2580–2588.
48. Combs CK, Karlo JC, Kao SC, Landreth GE (2001) beta-Amyloid stimulation
of microglia and monocytes results in TNFalpha-dependent expression of
inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 21:
1179–1188.
49. Choi SH, Lee DY, Ryu JK, Kim J, Joe EH, et al. (2003) Thrombin induces
nigral dopaminergic neurodegeneration in vivo by altering expression of death-
related proteins. Neurobiol Dis 14: 181–193.
50. Haddad JJ (2002) Antioxidant and prooxidant mechanisms in the regulation of
redox(y)-sensitive transcription factors. Cell Signal 14: 879–897.
51. La Rosa G, Cardali S, Genovese T, Conti A, Di Paola R, et al. (2004) Inhibition
of the nuclear factor-kappaB activation with pyrrolidine dithiocarbamate
attenuating inflammation and oxidative stress after experimental spinal cord
trauma in rats. J Neurosurg Spine 1: 311–321.
52. Bowie A, O’Neill LA (2000) Oxidative stress and nuclear factor-kappaB
activation: a reassessment of the evidence in the light of recent discoveries.
Biochem Pharmacol 59: 13–23.
53. Rahman A, Anwar KN, Minhajuddin M, Bijli KM, Javaid K, et al. (2004)
cAMP targeting of p38 MAP kinase inhibits thrombin-induced NF-kappaB
activation and ICAM-1 expression in endothelial cells. Am J Physiol Lung Cell
Mol Physiol 287: L1017–1024.
54. Aizawa T, Wei H, Miano JM, Abe J, Berk BC, et al. (2003) Role of
phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in
vascular smooth muscle cells. Circ Res 93: 406–413.
55. Verma IM (2004) Nuclear factor (NF)-kappaB proteins: therapeutic targets. Ann
Rheum Dis 63(Suppl 2): ii57–ii61.
56. Streit WJ, Semple-Rowland SL, Hurley SD, Miller RC, Popovich PG, et al.
(1998) Cytokine mRNA profiles in contused spinal cord and axotomized facial
PDE7 Inhibitors as New Drugs for SCI
PLoS ONE | www.plosone.org 14 January 2011 | Volume 6 | Issue 1 | e15937nucleus suggest a beneficial role for inflammation and gliosis. Exp Neurol 152:
74–87.
57. Genovese T, Mazzon E, Crisafulli C, Di Paola R, Muia C, et al. (2006)
Immunomodulatory effects of etanercept in an experimental model of spinal
cord injury. J Pharmacol Exp Ther 316: 1006–1016.
58. Smale G, Nichols NR, Brady DR, Finch CE, Horton WE, Jr. (1995) Evidence
for apoptotic cell death in Alzheimer’s disease. Exp Neurol 133: 225–230.
59. Beattie MS, Farooqui AA, Bresnahan JC (2000) Review of current evidence for
apoptosis after spinal cord injury. J Neurotrauma 17: 915–925.
60. Janicke RU, Sprengart ML, Wati MR, Porter AG (1998) Caspase-3 is required
for DNA fragmentation and morphological changes associated with apoptosis.
J Biol Chem 273: 9357–9360.
61. Beattie MS, Hermann GE, Rogers RC, Bresnahan JC (2002) Cell death in
models of spinal cord injury. Prog Brain Res 137: 37–47.
62. Chittenden T, Harrington EA, O’Connor R, Flemington C, Lutz RJ, et al.
(1995) Induction of apoptosis by the Bcl-2 homologue Bak. Nature 374:
733–736.
63. Bar-Peled O, Knudson M, Korsmeyer SJ, Rothstein JD (1999) Motor neuron
degeneration is attenuated in bax-deficient neurons in vitro. J Neurosci Res 55:
542–556.
64. Nesic-Taylor O, Cittelly D, Ye Z, Xu GY, Unabia G (2005) Exogenous Bcl-xL
fusion protein spares neurons after spinal cord injury. J Neurosci Res 79:
628–637.
65. Casha S, Yu WR, Fehlings MG (2001) Oligodendroglial apoptosis occurs along
degenerating axons and is associated with FAS and p75 expression following
spinal cord injury in the rat. Neuroscience 103: 203–218.
PDE7 Inhibitors as New Drugs for SCI
PLoS ONE | www.plosone.org 15 January 2011 | Volume 6 | Issue 1 | e15937